Hansa Biopharma Interim report January-September 2022
-
Upcoming milestones and news flow
2022 Anti-GBM: Initiation of phase 3 study
2022 NiceR: Completion of GLP tox studies
H2 2022 AMR Phase 2 study: First data read out
H2 2022 U.S. Kidney transplantation: Complete enrollment
H2 2022/H1 2023 GBS Phase 2 study: Complete enrollment
H1 2023 U.S. Kidney transplantation: Complete randomization
H2 2023 GBS Phase 2 study: First data read out
2023 Long-term follow-up data 5-years out in kidney transplantation
2024 Kidney transplantation US: BLA submission
-
Hansa Biopharma: Q3 Launch and Genetic exploratory progress
https://www.redeye.se/research/858658/hansa-biopharma-q3-launch-and-genetic-exploratory-progress
(Redeye)
Idefirix accounts a relatively solid Q3 despite holiday interruptions. This is combined with collaboration genetic progress which converts earlier cash considerations into Q3 sales support. We expect a positive reaction compared with the regional equity market but be aware of the non-recurring nature of collaboration related sales support.
-
"The current valuation is attractive for investors prepared to look into 2023 and beyond. Our base case value proposition is SEK 410 (Bear SEK 175 and Bull SEK 600) is under review. Hansa's Q3 result will likely trigger a positive reaction mainly based on very modest valuations, secured access to growth capital and a promising outlook over the next 12 to 24 months."
(Redeye)
-
Ja, men desværre har tilliden til aktien været tæt på et nulpunkt gennem længere tid.
Investorerne venter på, at se "penge i kassen" og ikke det modsatte kvartal efter kvartal. Derfor har det været en populær aktie hos shorterne i de seneste år. Men forhåbentlig ser vi en positiv resultat-vending i løbet af 2023.
Hansa Biopharma rapporterer et driftsresultat på SEK -140 millioner (-148) for tredje kvartal af 2022. Falder p.t. ca 6%.
-
Investor Road Show Presentation Q3 2022:
https://www.hansabiopharma.com/investors/presentations/
CC er igang!
-
Som jeg skrev tidligere, så lugter amerikanerne blod, og shorter Big time.
-
Hansa Biopharma: Klaus Sindahl, Head of Investor Relations presenterar på Redeye Investor AW - Göteborg 20 oktober 2022:
(Redeye)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind